Analysts Set Xencor, Inc. (NASDAQ:XNCR) Price Target at $34.38

Shares of Xencor, Inc. (NASDAQ:XNCR) have been given an average recommendation of “Buy” by the eight research firms that are covering the company, Marketbeat reports. Seven analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among analysts that have covered the stock in the last year is $34.38.

Several research firms have commented on XNCR. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, Wells Fargo & Company lowered their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in XNCR. Sterling Capital Management LLC lifted its position in Xencor by 732.4% during the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 1,040 shares during the period. GF Fund Management CO. LTD. purchased a new stake in shares of Xencor during the fourth quarter valued at approximately $34,000. GAMMA Investing LLC increased its position in shares of Xencor by 31.0% during the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after acquiring an additional 508 shares in the last quarter. Quarry LP raised its holdings in Xencor by 111.4% in the 3rd quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after acquiring an additional 2,108 shares during the last quarter. Finally, KBC Group NV lifted its position in Xencor by 26.0% in the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock valued at $90,000 after acquiring an additional 813 shares in the last quarter.

Xencor Price Performance

Xencor stock opened at $10.64 on Tuesday. The stock has a market cap of $749.72 million, a price-to-earnings ratio of -3.33 and a beta of 0.74. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The business has a 50-day simple moving average of $15.39 and a 200 day simple moving average of $20.01. Xencor has a 52 week low of $10.40 and a 52 week high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The firm had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. On average, research analysts forecast that Xencor will post -3.68 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.